Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. increased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 2,225.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 461,959 shares of the company's stock after purchasing an additional 442,090 shares during the quarter. Jacobs Levy Equity Management Inc. owned 1.07% of Kyverna Therapeutics worth $1,728,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in KYTX. China Universal Asset Management Co. Ltd. purchased a new position in Kyverna Therapeutics in the 4th quarter valued at about $34,000. Corton Capital Inc. acquired a new position in shares of Kyverna Therapeutics in the fourth quarter worth about $45,000. Corebridge Financial Inc. grew its stake in Kyverna Therapeutics by 42.3% during the 4th quarter. Corebridge Financial Inc. now owns 12,811 shares of the company's stock valued at $48,000 after purchasing an additional 3,810 shares in the last quarter. Bank of America Corp DE increased its holdings in Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company's stock worth $81,000 after purchasing an additional 6,400 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Kyverna Therapeutics by 31.1% in the 4th quarter. Rhumbline Advisers now owns 25,920 shares of the company's stock valued at $97,000 after purchasing an additional 6,153 shares in the last quarter. 18.08% of the stock is owned by institutional investors and hedge funds.

Kyverna Therapeutics Trading Down 4.0%

Kyverna Therapeutics stock traded down $0.10 during mid-day trading on Wednesday, reaching $2.30. The company's stock had a trading volume of 86,915 shares, compared to its average volume of 415,599. Kyverna Therapeutics, Inc. has a twelve month low of $1.78 and a twelve month high of $16.64. The business has a 50 day moving average price of $2.13 and a 200-day moving average price of $3.23. The firm has a market cap of $99.19 million, a price-to-earnings ratio of -0.68 and a beta of 2.17.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.21) by $0.18. On average, equities analysts expect that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating for the company in a research note on Tuesday, April 1st. HC Wainwright cut their target price on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating on the stock in a research note on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $18.33.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.